Advanced

Gene therapy and enhancement for diabetes (and other diseases) : The multiplicity of considerations

Bertolaso, Marta; Olsson, Jenny LU ; Picardi, Antonio and Rakela, Jorge (2010) In Diabetes/Metabolism Research and Reviews 26(7). p.520-524
Abstract

Gene therapy has reached the forefront of studies and research over the last 30 years because of its potential for curing, treating, and preventing diseases associated with DNA mutations. Type 1 and type 2 diabetes are two examples of very common polygenic and multifactorial diseases. The huge amount of scientific literature on this topic reflects a growing general interest in the possibilities of altering our genetic heritage and thus controlling the onset of diseases associated with mutations and relative risk factors. We have focussed on the new treatment opportunities and possibility of enhancing an individual's health, physical well-being, and even an individual's behaviour through technologies specially designed for therapeutic... (More)

Gene therapy has reached the forefront of studies and research over the last 30 years because of its potential for curing, treating, and preventing diseases associated with DNA mutations. Type 1 and type 2 diabetes are two examples of very common polygenic and multifactorial diseases. The huge amount of scientific literature on this topic reflects a growing general interest in the possibilities of altering our genetic heritage and thus controlling the onset of diseases associated with mutations and relative risk factors. We have focussed on the new treatment opportunities and possibility of enhancing an individual's health, physical well-being, and even an individual's behaviour through technologies specially designed for therapeutic purposes, which have been presented in literature. This historical perspective shows how this type of research, however, was immediately subjected to an ethical evaluation, especially regarding the decoding of the human genome and the questions raised by the alteration of our genetic heritage through new biotechnologies. Moreover, understanding the limitations of gene therapy protocol experiments and the multifactorial nature of many diseases, which have a genetic base, also contributes to these considerations.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Biological complexity, Diabetes mellitus, Enhancement, Ethics, Gene therapy
in
Diabetes/Metabolism Research and Reviews
volume
26
issue
7
pages
5 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:78651515191
ISSN
1520-7552
DOI
10.1002/dmrr.1116
language
English
LU publication?
no
id
039283a4-e877-4aa7-9795-0d49db432823
date added to LUP
2016-11-21 11:52:54
date last changed
2018-05-29 11:34:07
@article{039283a4-e877-4aa7-9795-0d49db432823,
  abstract     = {<p>Gene therapy has reached the forefront of studies and research over the last 30 years because of its potential for curing, treating, and preventing diseases associated with DNA mutations. Type 1 and type 2 diabetes are two examples of very common polygenic and multifactorial diseases. The huge amount of scientific literature on this topic reflects a growing general interest in the possibilities of altering our genetic heritage and thus controlling the onset of diseases associated with mutations and relative risk factors. We have focussed on the new treatment opportunities and possibility of enhancing an individual's health, physical well-being, and even an individual's behaviour through technologies specially designed for therapeutic purposes, which have been presented in literature. This historical perspective shows how this type of research, however, was immediately subjected to an ethical evaluation, especially regarding the decoding of the human genome and the questions raised by the alteration of our genetic heritage through new biotechnologies. Moreover, understanding the limitations of gene therapy protocol experiments and the multifactorial nature of many diseases, which have a genetic base, also contributes to these considerations.</p>},
  author       = {Bertolaso, Marta and Olsson, Jenny and Picardi, Antonio and Rakela, Jorge},
  issn         = {1520-7552},
  keyword      = {Biological complexity,Diabetes mellitus,Enhancement,Ethics,Gene therapy},
  language     = {eng},
  number       = {7},
  pages        = {520--524},
  publisher    = {John Wiley & Sons},
  series       = {Diabetes/Metabolism Research and Reviews},
  title        = {Gene therapy and enhancement for diabetes (and other diseases) : The multiplicity of considerations},
  url          = {http://dx.doi.org/10.1002/dmrr.1116},
  volume       = {26},
  year         = {2010},
}